

Oasmia to present at Aktiespararna's Småbolagsdagar on June 9

Uppsala, Sweden, June 2, 2021 – Oasmia Pharmaceutical's CEO, Dr Francois Martelet will present at Aktiespararna's Småbolagsdagar on June 9, 2021. The presentation starts at 09:30 CEST and will be broadcast live as a webcast at: www.aktiespararna.se/tv/live

The presentation will be available online the following day on www.aktiespararna.se/tv/evenemang and on Oasmia Pharmaceutical's website www.oasmia.com

For More Information:

Oasmia Pharmaceutical AB

Francois Martelet, Chief Executive Officer

Phone: +46 18-50 54 40

E-mail: IR@oasmia.com

Consilium Strategic Communications (For Oasmia)

Jonathan Birt, Chris Welsh, Ashley Tapp

Phone: +44 (0)20 3709 5700

E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB

Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Oasmia's proprietary drug delivery platform which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia's shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com.

Attachments

[Oasmia to present at Aktiespararna's Småbolagsdagar on June 9](#)